Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Prometheus Biosciences, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa)

Clinical trials sponsored by Prometheus Biosciences, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa), explained in plain language.

Now part of Merck & Co., Inc. MRK NYSE

A biopharmaceutical company developing precision immunology treatments, acquired by Merck.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet finished but already full! 1 Completed 1

New drug shows promise for tough Crohn's cases

Disease control Completed

This study tested a new drug called tulisokibart (PRA023) in 55 people with moderate-to-severe Crohn's disease who had not responded well to other treatments. The main goals were to check safety and see if the drug could improve gut healing and reduce symptoms. After 12 weeks, so…

Phase: PHASE2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control

Last updated Jul 24, 2026 00:00 UTC